Obalon Therapeutics, Inc.
OBLN · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $8 | $2 | $3 | $9 |
| % Growth | 404.2% | -51.6% | -63.9% | – |
| Cost of Goods Sold | $3 | $1 | $3 | $5 |
| Gross Profit | $5 | $1 | $0 | $4 |
| % Margin | 63.2% | 36.8% | 10.1% | 40.4% |
| R&D Expenses | $2 | $2 | $7 | $11 |
| G&A Expenses | $7 | $9 | $17 | $30 |
| SG&A Expenses | $10 | $9 | $17 | $30 |
| Sales & Mktg Exp. | $3 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $11 | $24 | $41 |
| Operating Income | -$7 | -$11 | -$23 | -$37 |
| % Margin | -83.3% | -670.2% | -708% | -406.2% |
| Other Income/Exp. Net | -$0 | -$2 | -$0 | -$0 |
| Pre-Tax Income | -$7 | -$12 | -$24 | -$37 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$12 | -$24 | -$37 |
| % Margin | -89.1% | -776.7% | -721.6% | -410.7% |
| EPS | -13.83 | -1.59 | -5.03 | -19.64 |
| % Growth | -769.8% | 68.4% | 74.4% | – |
| EPS Diluted | -13.83 | -1.59 | -5.03 | -19.64 |
| Weighted Avg Shares Out | 1 | 8 | 5 | 2 |
| Weighted Avg Shares Out Dil | 1 | 8 | 5 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$7 | -$11 | -$23 | -$37 |
| % Margin | -83.3% | -723.6% | -694.4% | -404.3% |